{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:39:57Z","timestamp":1792467597766,"version":"4.5.0"},"reference-count":38,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Exp Pathol"],"DOI":"10.62347\/wfcw1643","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T02:39:28Z","timestamp":1764297568000},"page":"535-545","source":"Crossref","is-referenced-by-count":1,"title":["Splenic megakaryocyte density in immune thrombocytopenia: insights from a histologic analysis of splenectomy specimens"],"prefix":"10.62347","volume":"18","author":[{"given":"Kei","family":"Koyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kühne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H and Vesely SK. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3: 3829-3866.","journal-title":"Blood Adv"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J and Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","unstructured":"Cines DB and Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB and George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010; 85: 174-180.","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","unstructured":"Nugent D, McMillan R, Nichol JL and Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production. Br J Haematol 2009; 146: 585-596.","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1600-0609.2005.00622.x","article-title":"Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura","volume":"76","author":"Zhang","year":"2006","unstructured":"Zhang F, Chu X, Wang L, Zhu Y, Li L, Ma D, Peng J and Hou M. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006; 76: 427-31.","journal-title":"Eur J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3389\/fimmu.2018.00880","article-title":"Emerging concepts in immune thrombocytopenia","volume":"9","author":"Swinkels","year":"2018","unstructured":"Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG and Jansen AJG. Emerging concepts in immune thrombocytopenia. Front Immunol 2018; 9: 880.","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","unstructured":"Zufferey A, Kapur R and Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 2017; 6: 16.","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjh.12480","article-title":"Cellular immune dysfunction in immune thrombocytopenia (ITP)","volume":"163","author":"McKenzie","year":"2013","unstructured":"McKenzie CG, Guo L, Freedman J and Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013; 163: 10-23.","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/jcm10040789","article-title":"Primary immune thrombocytopenia: novel insights into pathophysiology and disease management","volume":"10","author":"Singh","year":"2021","unstructured":"Singh A, Uzun G and Bakchoul T. Primary immune thrombocytopenia: novel insights into pathophysiology and disease management. J Clin Med 2021; 10: 789.","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","unstructured":"Audia S, Mahévas M, Samson M, Godeau B and Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017; 16: 620-632.","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/CLEP.S229266","article-title":"Treatment patterns among adults with primary immune thrombocytopenia diagnosed in hematology clinics in the United States","volume":"12","author":"McGrath","year":"2020","unstructured":"McGrath LJ, Kilpatrick K, Overman RA, Reams D, Sharma A, Altomare I, Wasser J and Brookhart MA. Treatment patterns among adults with primary immune thrombocytopenia diagnosed in hematology clinics in the United States. Clin Epidemiol 2020; 12: 435-445.","journal-title":"Clin Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2017.05.010","article-title":"Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea","volume":"155","author":"Lee","year":"2017","unstructured":"Lee JY, Lee JH, Lee H, Kang B, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Choi HS, Lee JS and Bang SM. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb Res 2017; 155: 86-91.","journal-title":"Thromb Res"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Frederiksen H and Ghanima W. Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. Eur J Intern Med 2017; 37: e23-e25.","DOI":"10.1016\/j.ejim.2016.09.001"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Godeau B. B-cell depletion in immune thrombocytopenia. Semin Hematol 2013; 50 Suppl 1: S75-S82.","DOI":"10.1053\/j.seminhematol.2013.03.014"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ajh.25776","article-title":"Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: results of an integrated database of five clinical trials","volume":"95","author":"Kuter","year":"2020","unstructured":"Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K and Olie R. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: results of an integrated database of five clinical trials. Am J Hematol 2020; 95: 643-651.","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/11207620-000000000-00000","article-title":"Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia","volume":"25","author":"Garnock-Jones","year":"2011","unstructured":"Garnock-Jones KP. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia. BioDrugs 2011; 25: 401-404.","journal-title":"BioDrugs"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","unstructured":"Podolanczuk A, Lazarus AH, Crow AR, Grossbard E and Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113: 3154-3160.","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.4049\/jimmunol.168.7.3675","article-title":"Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura","volume":"168","author":"Kuwana","year":"2002","unstructured":"Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y and Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168: 3675-82.","journal-title":"J Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09537104.2010.515697","article-title":"Durability and factors associated with long term response after splenectomy for primary immune thrombocytopenia (ITP) and outcome of relapsed or refractory patients","volume":"22","author":"Aleem","year":"2011","unstructured":"Aleem A. Durability and factors associated with long term response after splenectomy for primary immune thrombocytopenia (ITP) and outcome of relapsed or refractory patients. Platelets 2011; 22: 1-7.","journal-title":"Platelets"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3324\/haematol.2020.248385","article-title":"FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia","volume":"106","author":"Norris","year":"2021","unstructured":"Norris PAA, Segel GB, Burack WR, Sachs UJ, Lissenberg-Thunnissen SN, Vidarsson G, Bayat B, Cserti-Gazdewich CM, Callum J, Lin Y, Branch D, Kapur R, Semple JW and Lazarus AH. FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia. Haematologica 2021; 106: 250-254.","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi","year":"2018","unstructured":"Chaturvedi S, Arnold DM and McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood 2018; 131: 1172-1182.","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","unstructured":"Kojouri K, Vesely SK, Terrell DR and George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634.","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/rth2.12423","article-title":"Second-line treatments and outcomes for immune thrombocytopenia: a retrospective study with electronic health records","volume":"4","author":"Lal","year":"2020","unstructured":"Lal LS, Said Q, Andrade K and Cuker A. Second-line treatments and outcomes for immune thrombocytopenia: a retrospective study with electronic health records. Res Pract Thromb Haemost 2020; 4: 1131-1140.","journal-title":"Res Pract Thromb Haemost"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1182\/blood-2012-04-424648","article-title":"Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia","volume":"120","author":"Daridon","year":"2012","unstructured":"Daridon C, Loddenkemper C, Spieckermann S, Kühl AA, Salama A, Burmester GR, Lipsky PE and Dörner T. Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood 2012; 120: 5021-31.","journal-title":"Blood"},{"key":"ref25","unstructured":"Jiang DY and Li CY. Immunohistochemical study of the spleen in chronic immune thrombocytopenic purpura. With special reference to hyperplastic follicles and foamy macrophages. Arch Pathol Lab Med 1995; 119: 533-537."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjh.18309","article-title":"Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia","volume":"198","author":"Pizzi","year":"2022","unstructured":"Pizzi M, Vianello F, Binotto G, Vianelli N, Carli G, Auteri G, Nichele I, Sbaraglia M, Zoletto S, Scarmozzino F, Bresciani R, d’Amore F, Friziero A, Guzzardo V, Bertozzi I, Famengo B, d’Amore ESG, Sabattini E and Dei Tos AP. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia. Br J Haematol 2022; 198: 916-922.","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ejh.13547","article-title":"Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications","volume":"106","author":"Pizzi","year":"2021","unstructured":"Pizzi M, Friziero A, Vianello F, Binotto G, Da Dalt G, Zoletto S, Carraro E, Fassan M, Sbaraglia M, Sperti C, Baldan N, D’Amore F, Bertozzi I, Righi S, Pierobon ES, Moletta L, Capovilla G, Grego A, Sabattini E, Fabris F, Merigliano S and Dei Tos AP. Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications. Eur J Haematol 2021; 106: 281-289.","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PAS.0000000000000994","article-title":"Adult primary immune thrombocytopenia: spleen histology findings and outcomes according to rituximab use based on analysis of 41 cases","volume":"42","author":"Furudo&#xEF","year":"2018","unstructured":"Furudoï A, Rivière É, Lazaro E, Furudoï E, Viallard JF and Parrens M. Adult primary immune thrombocytopenia: spleen histology findings and outcomes according to rituximab use based on analysis of 41 cases. Am J Surg Pathol 2018; 42: 401-412.","journal-title":"Am J Surg Pathol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00277-011-1292-2","article-title":"Increased number of B-cells in the red pulp of the spleen in ITP","volume":"91","author":"Olsson","year":"2012","unstructured":"Olsson B, Ridell B, Jernås M and Wadenvik H. Increased number of B-cells in the red pulp of the spleen in ITP. Ann Hematol 2012; 91: 271-277.","journal-title":"Ann Hematol"},{"key":"ref30","unstructured":"Bowman HE, Pettit VD, Caldwell FT and Smith EB. Morphology of the spleen in idiopathic thrombocytopenic purpura. Lab Invest 1955; 4: 206-216."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/jcp.38.9.985","article-title":"Splenic pathology in immune thrombocytopenia","volume":"38","author":"Hayes","year":"1985","unstructured":"Hayes MM, Jacobs P, Wood L and Dent DM. Splenic pathology in immune thrombocytopenia. J Clin Pathol 1985; 38: 985-988.","journal-title":"J Clin Pathol"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Wang CW, Yu CY, Peng YJ, Wang CY, Chang WC and Huang GS. Focal extramedullary haematopoiesis of the spleen: unusual MR appearance with pathological correlation. Br J Radiol 2008; 81: e211-4.","DOI":"10.1259\/bjr\/13962743"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00000478-199003000-00003","article-title":"Splenic pathology in thrombotic thrombocytopenic purpura","volume":"14","author":"Saracco","year":"1990","unstructured":"Saracco SM and Farhi DC. Splenic pathology in thrombotic thrombocytopenic purpura. Am J Surg Pathol 1990; 14: 223-229.","journal-title":"Am J Surg Pathol"},{"key":"ref34","unstructured":"Chang CS, Li CY and Cha SS. Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med 1993; 117: 981-985."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M and George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-93.","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","unstructured":"Audia S, Mahévas M, Samson M, Godeau B and Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017; 16: 620-632.","journal-title":"Autoimmun Rev"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Kaznelson P. Thrombolytische purpura. Z Klin Med 1919; 87: 133-64.","DOI":"10.1038\/scientificamerican03011919-133asupp"}],"container-title":["International Journal of Clinical and Experimental Pathology"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ijcep\/18\/11\/ijcep0168309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:08:38Z","timestamp":1792465718000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ijcep\/18\/11\/ijcep0168309.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/wfcw1643","relation":{},"ISSN":["1936-2625"],"issn-type":[{"value":"1936-2625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}